ph365 ph365 net
ph365 ph365 net
Political will ‘all that is needed’ for new crossing points, UN’s Stewart saysANI Pharmaceuticals, Inc. ( NASDAQ:ANIP – Get Free Report ) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 2,350,000 shares, a growth of 27.7% from the November 30th total of 1,840,000 shares. Based on an average daily volume of 253,300 shares, the days-to-cover ratio is currently 9.3 days. Insider Activity at ANI Pharmaceuticals In other ANI Pharmaceuticals news, CFO Stephen P. Carey sold 7,500 shares of the business’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now owns 154,468 shares of the company’s stock, valued at $8,617,769.72. The trade was a 4.63 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website . Also, CEO Nikhil Lalwani sold 33,481 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $57.99, for a total transaction of $1,941,563.19. Following the transaction, the chief executive officer now directly owns 370,378 shares in the company, valued at $21,478,220.22. This represents a 8.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here . Insiders sold 42,231 shares of company stock worth $2,434,286 in the last ninety days. 12.70% of the stock is owned by company insiders. Hedge Funds Weigh In On ANI Pharmaceuticals Several large investors have recently bought and sold shares of the company. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of ANI Pharmaceuticals by 24.2% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,971 shares of the specialty pharmaceutical company’s stock worth $177,000 after purchasing an additional 579 shares during the last quarter. XTX Topco Ltd acquired a new stake in ANI Pharmaceuticals during the 2nd quarter worth approximately $207,000. HighTower Advisors LLC bought a new stake in ANI Pharmaceuticals during the 3rd quarter worth approximately $222,000. Profund Advisors LLC acquired a new position in ANI Pharmaceuticals in the 2nd quarter valued at approximately $225,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of ANI Pharmaceuticals during the second quarter valued at $228,000. 76.05% of the stock is currently owned by institutional investors. ANI Pharmaceuticals Price Performance ANI Pharmaceuticals ( NASDAQ:ANIP – Get Free Report ) last announced its quarterly earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a negative net margin of 1.28% and a positive return on equity of 15.87%. The company had revenue of $148.30 million during the quarter, compared to the consensus estimate of $144.37 million. During the same period in the prior year, the business earned $1.05 earnings per share. The company’s revenue for the quarter was up 12.5% compared to the same quarter last year. Research analysts anticipate that ANI Pharmaceuticals will post 3.87 EPS for the current fiscal year. Wall Street Analyst Weigh In A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and issued a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Monday, November 11th. Truist Financial raised their target price on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a report on Tuesday, October 22nd. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, September 7th. Raymond James increased their price target on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research report on Wednesday, September 18th. Finally, Piper Sandler began coverage on shares of ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price objective for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $77.71. Check Out Our Latest Stock Report on ANI Pharmaceuticals About ANI Pharmaceuticals ( Get Free Report ) ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products. Featured Articles Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter .World News Today Live Updates: In today’s rapidly changing world, staying updated with global news is essential. Our World News coverage offers comprehensive insights into key international events, from politics and economics to social movements and cultural shifts. Get the latest updates on geopolitical developments, policy changes, economic trends, and significant global issues that shape societies and influence lives across continents. With expert analysis and timely reporting, we bring you a clear view of the forces impacting today’s global landscape, keeping you informed and prepared. Explore stories that reveal how international events connect and affect communities worldwide, ensuring you never miss a moment. World News Today Live: Investigator flags 26 OnlyFans accounts for suspected child exploitationRio Tinto Group (OTCMKTS:RTNTF) Short Interest Up 28.6% in December
Jimmy Carter, the United States’ longest-lived president, was never afraid of speaking his mind. Forthright and fearless, the Nobel Prize winner took pot-shots at former prime minister Tony Blair and ex-US president George W Bush among others. His death came after repeated bouts of illness in which images of the increasingly frail former president failed to erase memories of his fierce spirit. Democrat James Earl “Jimmy” Carter Jr swept to power in 1977 with his Trust Me campaign helping to beat Republican president Gerald Ford. Serving as 39th US president from 1977 to 1981, he sought to make government “competent and compassionate” but was ousted by the unstoppable Hollywood appeal of a certain Ronald Reagan. A skilled sportsman, Mr Carter left his home of Plains, Georgia, to join the US Navy, returning later to run his family’s peanut business. A stint in the Georgia senate lit the touchpaper on his political career and he rose to the top of the Democratic movement. But he will also be remembered for a bizarre encounter with a deeply disgruntled opponent. The president was enjoying a relaxing fishing trip near his home town in 1979 when his craft was attacked by a furious swamp rabbit which reportedly swam up to the boat hissing wildly. The press had a field day, with one paper bearing the headline President Attacked By Rabbit. Away from encounters with belligerent bunnies, Mr Carter’s willingness to address politically uncomfortable topics did not diminish with age. He recently said that he would be willing to travel to North Korea for peace talks on behalf of US President Donald Trump. He also famously mounted a ferocious and personal attack on Tony Blair over the Iraq war, weeks before the prime minister left office in June 2007. Mr Carter, who had already denounced George W Bush’s presidency as “the worst in history”, used an interview on BBC radio to condemn Mr Blair for his tight relations with Mr Bush, particularly concerning the Iraq War. Asked how he would characterise Mr Blair’s relationship with Mr Bush, Mr Carter replied: “Abominable. Loyal, blind, apparently subservient. “I think that the almost undeviating support by Great Britain for the ill-advised policies of President Bush in Iraq have been a major tragedy for the world.” Mr Carter was also voluble over the Rhodesia crisis, which was about to end during his presidency. His support for Robert Mugabe at the time generated widespread criticism. He was said to have ignored the warnings of many prominent Zimbabweans, black and white, about what sort of leader Mugabe would be. This was seen by Mr Carter’s critics as “deserving a prominent place among the outrages of the Carter years”. Mr Carter has since said he and his administration had spent more effort and worry on Rhodesia than on the Middle East. He admitted he had supported two revolutionaries in Mugabe and Joshua Nkomo, and with hindsight said later that Mugabe had been “a good leader gone bad”, having at first been “a very enlightened president”. One US commentator wrote: “History will not look kindly on those in the West who insisted on bringing the avowed Marxist Mugabe into the government. “In particular, the Jimmy Carter foreign policy... bears some responsibility for the fate of a small African country with scant connection to American national interests.” In recent years Mr Carter developed a reputation as an international peace negotiator. He won the Nobel Peace Prize in 2002 for his commitment to finding peaceful solutions to international conflicts, his work with human rights and democracy initiatives, and his promotion of economic and social programmes. Mr Carter was dispatched to North Korea in August 2008 to secure the release of US citizen Aijalon Mahli Gomes, who had been sentenced to eight years of hard labour after being found guilty of illegally entering North Korea. He successfully secured the release of Mr Gomes. In 2010 he returned to the White House to greet President Barack Obama and discuss international affairs amid rising tensions on the Korean peninsula. Proving politics runs in the family, in 2013 his grandson Jason, a state senator, announced his bid to become governor in Georgia, where his famous grandfather governed before becoming president. He eventually lost to incumbent Republican Nathan Deal. Fears that Mr Carter’s health was deteriorating were sparked in 2015 when he cut short an election observation visit in Guyana because he was “not feeling well”. It would have been Mr Carter’s 39th trip to personally observe an international election. Three months later, on August 12, he revealed he had cancer which had been diagnosed after he underwent surgery to remove a small mass in his liver. Mr Obama was among the well-wishers hoping for Mr Carter’s full recovery after it was confirmed the cancer had spread widely. Melanoma had been found in his brain and liver, and Mr Carter underwent immunotherapy and radiation therapy, before announcing in March the following year that he no longer needed any treatment. In 2017, Mr Carter was taken to hospital as a precaution, after he became dehydrated at a home-building project in Canada. He was admitted to hospital on multiple occasions in 2019 having had a series of falls, suffering a brain bleed and a broken pelvis, as well as a stint to be treated for a urinary tract infection. Mr Carter spent much of the coronavirus pandemic largely at his home in Georgia, and did not attend Joe Biden’s presidential inauguration in 2021, but extended his “best wishes”. Former first lady Rosalynn Carter, the closest adviser to Mr Carter during his term as US president, died in November 2023. She had been living with dementia and suffering many months of declining health. “Rosalynn was my equal partner in everything I ever accomplished,” Mr Carter said in a statement following her death. “She gave me wise guidance and encouragement when I needed it. As long as Rosalynn was in the world, I always knew somebody loved and supported me.”New Syria PM calls for 'stability and calm'Mayor’s school board members oust Chicago schools CEO, face litigation
NoneGOJO President and CEO, Carey Jaros , Corporate Sales Director Moshe Lewis and National Sales VP, Ashley Fubini , received top honors for industry leadership AKRON, Ohio , Nov. 21, 2024 /PRNewswire/ -- GOJO President and CEO, Carey Jaros received the Jack D. Ramaley Industry Distinguished Service Award from ISSA in recognition of her outstanding service to the cleaning industry. With an audience of more than 500 industry colleagues, Jaros accepted the prestigious award, named after ISSA's executive director from 1960 to 1981. In accepting the award, Jaros praised ISSA, the GOJO team, distributor partners, and customers for their leadership in advancing the global cleaning industry through collaboration, mentorship, and participation in industry initiatives to help the sector grow and thrive. "I firmly believe that any time a leader is recognized that recognition ultimately belongs to their team, as none of us accomplish anything worthy of an award like this on our own," said Jaros. "So, it's my honor to accept the Jack D. Ramaley Award on behalf of all of Team GOJO, who are so passionate, hard-working, and purpose-driven, and our awesome distributor partners, who ultimately enable our PURELL products to get to people out in the world, and who are also dear friends and colleagues who push us to get better and better." In addition to Jaros' award, GOJO Corporate Sales Director, Moshe Lewis was selected as a member of the inaugural class of ISSA Emerging Leaders for 2024, and was the 1 st Runner Up for the Rising Star Award. Lewis is part of a group of 30 industry professionals that represent the next generation of leaders and was selected from a group of more than 100 nominations of industry professionals under the age of 40 for his outstanding contributions, leadership, and commitment to driving the industry forward. In addition to Jaros and Lewis' honors, the ISSA Hygieia Network awarded GOJO's National Sales Vice President Ashley Fubini the Rising Star of the Year Award. The award recognizes the significant achievements of an ISSA Hygieia member who has demonstrated consistent upward mobility in her career within the cleaning industry. Along with GOJO's multiple awards, the company continued to wow the ISSA Trade Show attendees with its newest dispensing system - PURELL ® ES 10. The PURELL ES10 is our simplest, most sustainable touch-free dispensing system. 3 This ground-breaking technology proves that less is more with less maintenance and less waste, all while delivering more ways to impress. Significant features of the new product include: Less Maintenance Never change batteries again 1 – a fresh battery is built into every refill. Work smarter – complimentary DISPENSER ADVISORTM app offers data-driven approach to help manage your dispenser fleet Less Waste 30% less plastic per refill 2 38% lower greenhouse gas emissions 2 Easy to recycle – for Improved recyclability from easy separation of the battery from plastic components for reduced battery and product waste. More Ways to Impress Exceptionally quiet dispensing Slim design fits and accentuates any environment GOJO is certified by the Women's Business Enterprise National Council (WBENC) as a Women's Business Enterprise, so purchasing these dispensing systems and PURELL ® refills can help customers achieve their supplier diversity goals and demonstrate their commitment to fostering diversity and equity. Businesses and government entities can now purchase the PURELL ® ES10 Dispensing Systems across the United States . Interested customers can visit (insert link) to learn more or contact their GOJO distributor. A video of the new dispensing system can be viewed here . About GOJO Industries GOJO is a Purpose-driven, 3rd generation Family Enterprise whose market-leading PURELL® soap, hand sanitizer, surface sprays and wipes are used around the world to help keep people healthy and well. A WBENC-certified women-owned business, for more than 75 years, GOJO has used science-based innovation to set new standards in safety, efficacy, and sustainability for both consumers and in public spaces like hospitals, schools, restaurants. GOJO is headquartered in Akron, Ohio with manufacturing facilities located in Northeast Ohio . For more information on GOJO Industries, please visit GOJO.com . Footnotes: 1 Per standard use under normal usage conditions 2 Compared with ES8 3 Has less 30% less plastic per refill and a 38% reduction in greenhouse gas emissions compared to ES8 system. View original content to download multimedia: https://www.prnewswire.com/news-releases/gojo-shines-at-issa-trade-show-celebrating-success-with-multiple-industry-awards-302313642.html SOURCE GOJO Industries, Inc.
The Container Store, buffeted by rough housing market and competition, seeks bankruptcy protectionWho is the unknown blogger who is influencing Donald Trump's coming administration? Here's all about the little known bloggerNYS Division of Consumer Protection provides tips for shopping returns
Mayor Ken Sim says abolition of elected park board will mean $70M in savings
Delhi University is currently deliberating the inclusion of courses centered around the concept of "Viksit Bharat" (Developed India) and the Bhagavad Gita. The Delhi University is mulling over adding value added courses to their curriculum across courses and years. The value-added courses which are being deliberated upon are- 1. Introduction to Viksit Bharat 2. The Science of happiness 3. Gita for Holistic Life 4. Gita and Leadership Excellence 5. Gita for Sustainable Universe 6. Gita for Navigating Life challenges An academic counsel is all set to discuss the details of the courses on the 27th of December, which will decide the further course of action on these courses. The proposal was also discussed at the Standing committee, which has deferred it. A member of the committee, requesting anonymity, has stated that these value-added courses will not benefit the students, and it seems like a "ploy" to impress political bosses. Get Latest News Live on Times Now along with Breaking News and Top Headlines from Delhi and around the world.
Dazostinag sodium is under clinical development by and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Dazostinag sodium overview Dazostinag sodium (TAK-676) is under development for the treatment of advanced or metastatic solid tumors including non-small cell lung cancer, triple-negative breast cancer (TNBC), oropharyngeal cancer, colorectal cancer and head and neck cancer squamous cell carcinoma. The drug candidate is cyclic purine dinucleotide and acts by targeting stimulator of interferon genes (STING/TMEM173). It is a new molecular entity. It is administered via intravenous route. Takeda Pharmaceutical overview (Takeda) is a global pharmaceutical company primarily engaged in the research, development, production, and commercialization of biopharmaceutical products. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder; and its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. While the company markets its pharmaceutical products directly, it also collaborates with marketing alliance partners in worldwide. Takeda operates in various countries worldwide, including Japan, the US, Europe, Latin America, Africa, the Middle East, and the Asia Pacific region. Takeda is headquartered in Tokyo, Japan. For a complete picture of Dazostinag sodium’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .Oscar-winning actor Jamie Foxx has opened up about the medical emergency he faced last year , revealing that he had a brain bleed that led to a stroke. The Hollywood star detailed the struggles he had with his health last year. "It is a mystery," he said. "We still don't know exactly what happened to me." "April 11, I was having a bad headache and I asked my boy for an aspirin. And I realized quickly that when you're in a medical emergency, your boys don't know what the f--- to do," he said. "Before I could get the aspirin I went out," he said. "I don't remember 20 days." Foxx thanked his sister , who he said was "4 foot 11 of nothing but pure love," for driving him around Atlanta to find a hospital. They ended up at Piedmont Hospital, where a doctor told them that Foxx was having a brain bleed that had led to a stroke and that he would die without an operation, the actor said. After the operation, doctors said that Foxx might make a full recovery "but it's going to be the worst year of his life," Foxx recounted. Foxx's family kept him out of the public eye because he was "so dizzy" that his head would bob around and his daughter was concerned that people would turn him into an internet meme if they saw his condition, he said. On May 4, he remembers waking up in a wheelchair and not being able to walk, and reacting in shock when his friend told him he'd had a stroke. "Jamie Foxx don't get strokes," the actor remembered saying. He was then flown to Chicago for rehab, where he says he was told to drop the "arrogant" act if he wanted to make a full recovery. The actor was hospitalized in April 2023 after having a then-undisclosed health crisis while filming a Netflix film in Atlanta. At the time of his hospitalization, his daughter Corinne Foxx said on social media that her father had suffered a "medical complication," but those close to him largely stayed tight-lipped about the actor's condition, in keeping with his penchant for privacy. In July 2023, Foxx posted an Instagram video update in which he addressed the speculation about what led to his hospitalization, although he did not reveal details of what happened. "I know a lot of people were waiting or wanting to hear updates but to be honest with you, I just didn't want you to see me like that, man," he said in the video. "I want you to see me laughing, having a good time, partying, cracking a joke, doing a movie, television show. I didn't want you to see me with tubes running out of me and trying to figure out if I was gonna make it through." Foxx shared another health update on his verified social media in August 2023. "You're looking at a man who is thankful... finally startin' to feel like myself..." he wrote at the time. "It's been an unexpected dark journey... but I can see the light." This past summer, in a video shared to TikTok , the "Ray" actor told a crowd of well-wishers that his issue began with a "bad headache" and was then "gone for 20 days." In that video, he was seen sharing that he did not "remember anything."NFC's No. 1 seed comes down to Vikings-Lions showdown at Detroit in Week 18
Cannabis Stocks Feel The Burn: Matt Gaetz Bows Out As Trump's Attorney General NomineeSNAX stock hits 52-week low at $0.74 amid market challenges
Lesabelimab is under clinical development by Dragonboat Biopharmaceutical (Shanghai) and currently in Phase I for Endometrial Cancer. According to GlobalData, Phase I drugs for Endometrial Cancer have an 81% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval. Lesabelimab overview lesabelimab is under development for the treatment of advanced malignant tumors including invasive bladder cancer, head and neck squamous cell carcinoma, esophageal squamous cell carcinoma and penile squamous cell carcinoma, endometrial cancer, cervical cancer, ovarian cancer, colorectal cancer, advanced non-clear cell renal cancer and advanced penile cancer, and unspecified indication. It acts by targeting PD L1. The drug candidate is administered as injection. lesabelimab is under development for the treatment of nasopharyngeal carcinoma and solid tumors. Dragonboat Biopharmaceutical (Shanghai) overview Dragonboat Biopharmaceutical (Shanghai) (Dragonboat Biopharmaceutical), a subsidiary of Guilin Sanjin Pharmaceutical Co Ltd, is a biopharmaceutical company that researches and develops biologics for cancers and autoimmune diseases. The company pipeline product includes BC003, BC001, BC005, BC006, BC007, BC008, BC010, BC011 and BCT2101. Dragonboat Biopharmaceutical drug candidate indications include solid tumors, tenosynovial giant cell tumors, asthma, gastric cancer and pancreatic cancer among others. It also utilizes an In-house systemic platform. The company operates a drug research and development center that covers early discovery, preclinical research, IND, clinical research, biologics license application and manufacturing. Dragonboat Biopharmaceutical is headquartered in Shanghai, China. For a complete picture of Lesabelimab’s drug-specific PTSR and LoA scores, This content was updated on 12 April 2024 From Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors. , the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s .Jimmy Carter had the longest post-presidency of anyone to hold the office, and one of the most active. Here is a look back at his life. 1924 — Jimmy Carter was born on Oct. 1 to Earl and Lillian Carter in the small town of Plains, Georgia. 1928 — Earl Carter bought a 350-acre farm 3 miles from Plains in the tiny community of Archery. The Carter family lived in a house on the farm without running water or electricity. 1941 — He graduated from Plains High School and enrolled at Georgia Southwestern College in Americus. 1942 — He transferred to Georgia Institute of Technology in Atlanta. 1943 — Carter’s boyhood dream of being in the Navy becomes a reality as he is appointed to the U.S. Naval Academy in Annapolis, Maryland. 1946 — He received his naval commission and on July 7 married Rosalynn Smith of Plains. They moved to Norfolk, Virginia. 1946-1952 — Carter’s three sons are born, Jack in 1947, Chip in 1950 and Jeff in 1952. 1962-66 — Carter is elected to the Georgia State Senate and serves two terms. 1953 — Carter’s father died and he cut his naval career short to save the family farm. Due to a limited income, Jimmy, Rosalynn and their three sons moved into Public Housing Apartment 9A in Plains. 1966 — He ran for governor, but lost. 1967 — Jimmy and Rosalynn Carter’s fourth child, Amy, is born. 1971 — He ran for governor again and won the election, becoming Georgia’s 76th governor on Jan. 12. 1974 — Carter announced his candidacy for president. 1976 — Carter was elected 39th president on Nov. 2, narrowly defeating incumbent Gerald Ford. 1978 — U.S. and the Peoples’ Republic of China establish full diplomatic relations. President Carter negotiates and mediates an accord between Egypt and Israel at Camp David. 1979 — The Department of Education is formed. Iranian radicals overrun the U.S. Embassy and seize American hostages. The Strategic Arms Limitations Treaty is signed. 1980 — On March 21, Carter announces that the U.S. will boycott the Olympic Games scheduled in Moscow. A rescue attempt to get American hostages out of Iran is unsuccessful. Carter was defeated in his bid for a second term as president by Ronald Reagan in November. 1981 — President Carter continues to negotiate the release of the American hostages in Iran. Minutes before his term as president is over, the hostages are released. 1982 — Carter became a distinguished professor at Emory University in Atlanta, and founded The Carter Center. The nonpartisan and nonprofit center addresses national and international issues of public policy. 1984 — Jimmy and Rosalynn Carter volunteer one week a year for Habitat for Humanity, a nonprofit organization that helps needy people in the United States and in other countries renovate and build homes, until 2020. He also taught Sunday school in the Maranatha Baptist Church of Plains from the mid-’80s until 2020. 2002 — Awarded the Nobel Peace Prize. 2015 — Carter announced in August he had been diagnosed with melanoma that spread to his brain. 2016 — He said in March that he no longer needed cancer treatment. 2024 — Carter dies at 100 years old. Sources: Cartercenter.org, Plains Historical Preservation Trust, The Associated Press; The Brookings Institution; U.S. Navy; WhiteHouse.gov, Gallup
